Fulcrum (FULC) Gains 29.16% on August 5

Equities Staff  |

Shares of Fulcrum Therapeutics Inc (NASDAQ: FULC) rose 29.16% Friday.

As of 11:56:05 est, Fulcrum is currently sitting at $8.01 and has climbed $1.84 per share.

Fulcrum has moved 30.84% over the last 30 days and has a YTD change of 59.47% based on the most recent close.

The company anticipates its next earnings on 2022-08-09.

For technical charts, analysis, and more on Fulcrum visit the company profile.

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.

To get more information on Fulcrum Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Fulcrum Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

testforhref
The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content